These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 20050385)

  • 1. Dabigatran versus warfarin in patients with atrial fibrillation.
    Barry M
    N Engl J Med; 2009 Dec; 361(27):2674; author reply 2675. PubMed ID: 20050385
    [No Abstract]   [Full Text] [Related]  

  • 2. Dabigatran versus warfarin for venous thromboembolism.
    Teachey DT
    N Engl J Med; 2010 Mar; 362(11):1050; author reply 1050-1. PubMed ID: 20301800
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation.
    Shah SV; Gage BF
    Circulation; 2011 Jun; 123(22):2562-70. PubMed ID: 21606397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Replacing aspirin and warfarin for secondary stroke prevention: is it worth the costs?
    Hankey GJ
    Curr Opin Neurol; 2010 Feb; 23(1):65-72. PubMed ID: 19949330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral anticoagulants for atrial fibrillation: Which one to choose?
    Ribowsky JH; Ismael AG
    Adv NPs PAs; 2012 May; 3(5):31-2. PubMed ID: 22670305
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden.
    Davidson T; Husberg M; Janzon M; Oldgren J; Levin LÅ
    Eur Heart J; 2013 Jan; 34(3):177-83. PubMed ID: 22733833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
    Berg AM
    Ann Intern Med; 2011 Apr; 154(8):570; author reply 570-1. PubMed ID: 21502659
    [No Abstract]   [Full Text] [Related]  

  • 8. Dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
    Edwards DB; Silverberg J
    Ann Intern Med; 2011 Apr; 154(8):570; author reply 570-1. PubMed ID: 21502658
    [No Abstract]   [Full Text] [Related]  

  • 9. Dabigatran etexilate, a new oral direct thrombin inhibitor, for stroke prevention in patients with atrial fibrillation.
    Siddiqui FM; Qureshi AI
    Expert Opin Pharmacother; 2010 Jun; 11(8):1403-11. PubMed ID: 20446854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data.
    Ma TK; Yan BP; Lam YY
    Pharmacol Ther; 2011 Feb; 129(2):185-94. PubMed ID: 20920530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective.
    Sorensen SV; Kansal AR; Connolly S; Peng S; Linnehan J; Bradley-Kennedy C; Plumb JM
    Thromb Haemost; 2011 May; 105(5):908-19. PubMed ID: 21431243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark.
    Langkilde LK; Bergholdt Asmussen M; Overgaard M
    J Med Econ; 2012; 15(4):695-703. PubMed ID: 22397590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insights from the dabigatran versus warfarin in patients with atrial fibrillation (RE-LY) trial.
    Khoo CW; Lip GY
    Expert Opin Pharmacother; 2010 Mar; 11(4):685-7. PubMed ID: 20105114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dabigatran etexilate: a pharmacoeconomic review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
    McKeage K
    Pharmacoeconomics; 2012 Sep; 30(9):841-55. PubMed ID: 22734683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses.
    Pink J; Lane S; Pirmohamed M; Hughes DA
    BMJ; 2011 Oct; 343():d6333. PubMed ID: 22042753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dabigatran versus warfarin for patients with non-valvular atrial fibrillation: is the patient the winner?
    Grave S
    Aust Nurs J; 2011 Dec-2012 Jan; 19(6):30-3. PubMed ID: 22329103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dabigatran emerges as safe and effective warfarin alternative. The recently approved drug is more expensive, but appears to be more predictable.
    Heart Advis; 2011 Jan; 14(1):4. PubMed ID: 22973590
    [No Abstract]   [Full Text] [Related]  

  • 18. Stop the clots, but at what cost? Pharmacoeconomics of dabigatran etexilate for the prevention of stroke in subjects with atrial fibrillation: a systematic literature review.
    Marshall S; Fearon P; Dawson J; Quinn TJ
    Expert Rev Pharmacoecon Outcomes Res; 2013 Feb; 13(1):29-42. PubMed ID: 23402443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should dabigatran replace warfarin for stroke prevention in AF?
    Drug Ther Bull; 2011 Oct; 49(10):114-7. PubMed ID: 21994438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stroke prophylaxis with warfarin or dabigatran for patients with non-valvular atrial fibrillation-cost analysis.
    Ali A; Bailey C; Abdelhafiz AH
    Age Ageing; 2012 Sep; 41(5):681-4. PubMed ID: 22378612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.